Adaptimmune Therapeutics plc (MUN:473A)

Germany flag Germany · Delayed Price · Currency is EUR
0.0210
0.00 (0.00%)
At close: Feb 27, 2026
2.44%
Market Cap 4.49M
Revenue (ttm) 55.42M
Net Income (ttm) -144.55M
Shares Out n/a
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 0.0210
Previous Close 0.0210
Day's Range 0.0210 - 0.0210
52-Week Range 0.0205 - 0.0340
Beta n/a
RSI n/a
Earnings Date Mar 5, 2026

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA (famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment of synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company al... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Employees 506
Stock Exchange Munich Stock Exchange
Ticker Symbol 473A
Full Company Profile

Financial Performance

In 2024, Adaptimmune Therapeutics's revenue was $178.03 million, an increase of 195.34% compared to the previous year's $60.28 million. Losses were -$70.81 million, -37.81% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.